Sökning: "Sara Mangsbo"

Visar resultat 6 - 10 av 10 avhandlingar innehållade orden Sara Mangsbo.

1. 6. Dissecting the Microenvironment of Urothelial Bladder Cancer : Therapy, Modelling and Biomarkers

   Författare :Iliana Kyriaki Kerzeli; Sara Mangsbo; Tania de Gruijl; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Immuno-oncology; Tumor immunology; MALT1 inhibition; Urothelial bladder cancer; Tumor microenvironment; Immunologi; Immunology; Oncology; Onkologi; Urologi; Urology;

   Sammanfattning : The complexity of the tumor microenvironment (TME) impacts therapy responses and the survival of cancer patients. The scope of this thesis is to study the effects of immune modulation on tumor-infiltrating leukocytes, and to explore the TME of urothelial cancer to provide the research society with new knowledge and potential therapeutic targets. LÄS MER

3. 7. CD40L Gene Therapy for Solid Tumors

   Författare :Lina Liljenfeldt; Thomas Tötterman; Angelica Loskog; Sara Mangsbo; Evren Alici; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; CD40L; adenovirus; tumor immunology; tumor microenvironment; immunotherapy; local immunotherapy; antigen presentation; Immunologi; Immunology;

   Sammanfattning : Adenoviral CD40L gene therapy (AdCD40L) is a strong inducer of anti-tumor immune responses via its activation of dendritic cells (DCs). Activated DCs can in turn activate T cells, which are key players in an efficient anti-tumor response.This thesis includes three papers that focus on different aspects of AdCD40L gene therapy. LÄS MER

4. 8. Enhancing the therapeutic effect of biological drugs with protein engineering : Focusing on pre-clinical Alzheimer’s disease therapy

   Författare :Fadi Rofo; Greta Hultqvist; Stina Syvänen; Sara Mangsbo; Joy Zuchero; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer’s disease; amyloid-beta; blood-brain barrier; transferrin receptor; protein-drugs; multivalent-bispecific antibodies;

   Sammanfattning : Aggregation of the amyloid-β peptide (Aβ) is one of the main pathological hallmarks in Alzheimer’s disease (AD). The soluble Aβ aggregates (oligomers and protofibrils) have shown to be the most harmful species. Hence, targeting these aggregates can be of therapeutic potential. LÄS MER

5. 9. Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies

   Författare :Linda Sandin; Thomas Tötterman; Mangsbo Sara; Fredrik Eriksson; Loskog Angelica; Ola Winqvist; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; in situ checkpoint blockade; antibody-mediated tumor immunotherapy; CTLA-4; CD40; monoclonal antibodies; experimental animal model; Fc gamma receptor; Medical Science; Medicinsk vetenskap;

   Sammanfattning : Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. LÄS MER

7. 10. Experimental treatment of patients with disseminated malignant melanoma

   Författare :Aglaia Schiza; Gustav Ullenhag; Angelica Loskog; Sara Mangsbo; Thomas Tötterman; Ola Winqvist; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Malignant melanoma; AdCD40L; immunotherapy; proteomics; DW-MRI; FDG-PET CT; prediction; early response; BRAF-inhibitor; vemurafenib; Oncology; Onkologi;

   Sammanfattning : Malignant melanoma (MM) is the deadliest skin cancer with an ever-increasing incidence. New treatments have improved the prognosis for patients with advanced MM. Still, most patients do not respond, and the side effects can be severe, underlining the need for better therapies. LÄS MER